Spiegel Online

Dienstag, 19. November 2019


BUSINESS WIRE: Gilead Sciences' Chief Scientific Officer John McHutchison to Leave the Company

17.07.2019, 14:30 Uhr


FOSTER CITY, Calif. --(BUSINESS WIRE)-- 17.07.2019 --

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John McHutchison, AO, MD, Chief Scientific Officer and Head of Research & Development, has decided to leave the company, effective next month. The company will immediately commence a search for his successor.

Dr. McHutchison joined Gilead in 2010 and under his leadership, Gilead has developed five medicines that have been used by more than 3.2 million people around the world for the curative treatment of chronic hepatitis C, and treatment of chronic hepatitis B. He also oversaw the company's expansion into oncology with the development of Gilead's first cancer medicine, Zydelig® (idelalisib). He was appointed Chief Scientific Officer in March 2018. During his tenure, he has been responsible for broadening and overseeing the company's Research and Development pipeline, advancing candidates in new therapeutic areas, including oncology, cell therapy and inflammation.

"Over the past nine years, John's scientific contributions and leadership have played an instrumental role in shaping our research efforts and in improving care for millions of patients with life-threatening illnesses," said Daniel O'Day, Chairman and Chief Executive Officer of Gilead. "Under his guidance, the company was able to rapidly advance our hepatitis C portfolio, enabling therapies to reach people in need at an unprecedented pace, and he has continued to build on that work by helping the company expand its therapeutic areas of focus. We are grateful to John for his many contributions and wish him the best."

"It has been a privilege to work alongside many exceptionally talented scientists," said Dr. McHutchison. "I am grateful for the opportunity to make a difference in the lives of people with serious illnesses and confident that Gilead will continue to advance important new medicines for generations of patients to come."


About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information about Gilead, please visit the company's website at, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Sung Lee, Investors
(650) 524-7792

Amy Flood, Media
(650) 522-5643

Weitere Nachrichten

16:54 BUSINESS WIRE: Britischer Taschenhersteller Bucklesbury profitiert vom globalen Trend zu mehr Diversität in der Unternehmensführung
15:55 BUSINESS WIRE: Globaler Markt für True-Wireless-Kopfhörer erreicht im dritten Quartal 2019 33 Millionen Einheiten
15:45 BUSINESS WIRE: ADVA und PSNC zeigen 1200G Datenkanal auf der SC19
15:20 BUSINESS WIRE: SLM Solutions Group AG und Divergent Technologies unterzeichnen Absichtserklärung zum Kauf von AM-Maschinen der nächsten Generation und zur weiteren Vertiefung ihrer strategischen Partnerschaft
15:05 IRW-PRESS: Goldsource Mines Inc.: Goldsource Mines bestellt Drew Anwyll in sein Board
15:05 IRW-PRESS: Great Atlantic Resources Corp. : Great Atlantic leitet im Vanadiumkonzessionsgebiet Glenelg im Südwesten von New Brunswick ein Diamantbohrprogramm ein
15:04 IRW-PRESS: EnWave Corporation: EnWave unterzeichnet Technologiebewertung und Lizenzoptionsvertrag mit der Firma - Pick-One entwickelt REV™ Snacks in Mexiko
15:00 BUSINESS WIRE: Positive Pivotal Data for Daiichi Sankyo’s DS-8201 ([Fam]-Trastuzumab Deruxtecan) in Patients with HER2 Positive Metastatic Breast Cancer to be Presented at SABCS
14:06 IRW-PRESS: RAPID DOSE THERAPEUTICS: Health Canada erteilt Rapid Dose Therapeutics eine Lizenz für die Verarbeitung von Cannabis
13:37 IRW-PRESS: Gatling Exploration: Gatling forciert Bohrprogramm und nimmt drittes Bohrgerät zur Erprobung des 4,5 km langen mineralisierten Trends im Goldprojekt Larder in Ontario in Betrieb